Aims To evaluate the efficacy and safety of elobixibat in patients with diabetes and concomitant chronic constipation. Methods This was a single-center, single-arm study. Thirty-three patients with diabetes and chronic constipation, as defined by the Rome IV criteria, were treated with elobixibat (10 mg/day) for 8 weeks. Patients recorded stool properties, including spontaneous bowel movements (SBMs) and stool consistency, according to the Bristol Stool Form Scale (BSFS). Quality of life for constipation was evaluated with the Japanese version of the Patient Assessment of Constipation Quality of Life (JPAC-QOL). Results Of the 33 eligible patients, 30 completed the study. Elobixibat significantly increased the median (interquartile range) frequency of SBMs per week, from 5.0 (3.0–7.0) at baseline to 6.0 (4.0–7.0] at week 8 (p = 0.030). After 8 weeks, the BSFS score approached 4; the score for normal stool consistency and the JPAC-QOL score significantly improved from 1.05 ± 0.40 at baseline to 0.94 ± 0.53 (p = 0.048); and glycated albumin and serum lipid profiles significantly improved. Stratified analysis revealed that SBMs increased especially in patients with low SBM frequency, in particular in women, older adults, patients without overweight, patients with a long duration of constipation, and patients with diabetic neuropathy. No serious adverse events occurred. Conclusions Among patients with diabetes who met the Rome IV criteria for constipation, elobixibat was effective, especially in those with few SBMs at baseline. Improvements in lipid profiles could be an advantage of elobixibat compared with other laxatives. Clinical Trial Registry Japan Registry of Clinical Trials registration number: jRCTs031190092
Breath acetone (BrAce) has been reported to be useful for monitoring the pathophysiology of patients with diabetes. However, devices that measure BrAce are expensive, complex and uncommon. The FM-001, originally designed to monitor a marker of weight loss in healthy people, is a device for measuring BrAce. The FM-001 is a loading semiconducting gas sensor that is a simple and reusable device. The aim of this study was to evaluate the correlation between blood total ketone bodies (TKB) and BrAce measured with the FM-001 in patients with diabetes. Furthermore, through evaluation of that correlation, we sought to detect patients at high risk of developing diabetic ketoacidosis (DKA). Thirty-five participants (age 52 [40–57], T2DM 32, T1DM 3) were enrolled. Scatter plots and linear regression lines relating BrAce to TKB and the correlation coefficients were calculated. Receiver-operating characteristic analysis was performed to determine the cut-off for predicting patients prone to DKA. The results showed that BrAce strongly correlates with TKB (R = 0.828), and the correlation was stronger in patients whose serum C-peptide was not low. The optimal BrAce cut-off for predicting risk of developing DKA was 3400 ppb (AUC 0.924, sensitivity 73.3%, specificity 100%), which corresponds to a TKB ⩾ 1000 µmol l−1. BrAce also weakly correlated with free fatty acid. Thus, BrAce levels measured with the FM-001 strongly correlate with TKB, even in patients with diabetes. This suggests the FM-001 is a simple and potentially useful method for detecting diabetic ketosis. (UMIN-ID: UMIN000038086)
10 October 2025 in Diabetes Research and Clinical Practice
Diabetes stigma is an important issue, and healthcare providers may inadvertently perpetuate it. However, the extent to which future physicians-medical students and residents-are aware of diabetes stigma and advocacy remains poorly understood. This first real-world study aimed to assess their understanding of diabetes stigma and advocacy and identify the needs for strategic interventions in medical education. We conducted a questionnaire-based survey between July 2024 and March 2025 among medical students at three training stages (preclinical, clinical lectures, and clinical training group) and residents from two universities and university hospitals in eastern and western Japan. From 1607 potential participants, 921 responses were analyzed. Overall, 57·0% and 25·9% of participants reported awareness of diabetes stigma and advocacy, respectively. Awareness significantly increased with advancing training stage compared with the preclinical group (p < 0·01). Despite this trend, nearly half of them across all training stages had misconceptions and limited knowledge about diabetes. Japanese future physicians demonstrated limited understanding of diabetes stigma and advocacy, although clinical education appeared to improve awareness. These findings highlight the need for a structured, multi-stage framework within medical education to more effectively address stigma and prepare future physicians to contribute to its eradication.
Aim: An insulin dose of 0.1 U/kg/h recommended by Western guidelines occasionally induces a precipitous decreasing blood glucose in Asian diabetic ketoacidosis (DKA). It is known that clinical factors, such as insulin sensitivity, differ between Asians and Americans/Europeans. We investigated how treatment options affect the time to DKA resolution to determine the optimal treatment for Asian DKA patients.Methods: This was a retrospective cohort study from a single institution in Japan. A total of 34 adult DKA patients were observed. Baseline characteristics and treatment‐related parameters were compared between patients whose DKA was resolved within 18 h and those in which it was not.Results: Significant differences were observed in the initial insulin dose (mean [standard deviation]: 0.053 [0.021] versus 0.031 [0.014] U/kg/h; P = 0.003) and the baseline β‐hydroxybutyrate (7.2 [3.2] versus 9.9 [2.6] mmol/L; P = 0.024) and levels (11.2 [4.1] versus 7.7 [3.1] mmol/L; P = 0.014). Multivariable logistic regression analysis revealed that the initial insulin dose was significantly associated with early resolution of DKA and was independent of basal conditions. Receiver operating characteristic curve analysis indicated that the optimal cut‐off point for the initial insulin dose was 0.051 U/kg/h. With an initial insulin dose of 0.051 U/kg/h or higher, early resolution of DKA was obtained in 92.9% of patients.Conclusion: An initial insulin dose of more than 0.05 U/kg/h provides an early resolution of DKA in Asian patients. Lower insulin doses significantly delay resolution. These results provide practical information for acute phase treatment of Asian DKA.
In Japan, the Corticotropin-releasing hormone (CRH) stimulation test is widely used to evaluate secondary adrenal insufficiency (SAI); however, the insulin tolerance test (ITT) is sometimes required to assess hypothalamic dysfunction. This study aimed to identify the clinical conditions in which the ITT is necessary in addition to CRH testing. We retrospectively analyzed 69 patients who underwent both tests between August 2015 and December 2024. Forty-three patients with insufficient cortisol responses during the ITT were diagnosed with SAI and the others with non-SAI. Among SAI cases, cortisol level ≥18 μg/dL during CRH testing defined hypothalamic SAI and <18 μg/dL defined pituitary SAI. Clinical profiles and ACTH responses were compared. Pituitary SAI was associated with tumors, immune-related adverse events, glucocorticoids, COVID-19, hypophysitis and empty sella. Hypothalamic SAI was mainly associated with tumors, opioids, and COVID-19. During CRH testing, ACTH responses alone poorly distinguished hypothalamic SAI from non–adrenal insufficiency among patients with normal cortisol responses to CRH; however, a specific pattern of low basal level combined with a high peak of ACTH after CRH stimulation suggested hypothalamic SAI. In addition, a peak cortisol level <12 μg/dL in the growth hormone-releasing peptide-2 (GHRP-2) stimulation test was also specific to hypothalamic SAI among patients with normal cortisol responses to CRH. In conclusion, even when cortisol responses to CRH appear adequate, the ITT remains necessary for patients with clinical or etiological features suggestive of hypothalamic dysfunction. When the ITT is contraindicated, analyzing ACTH values during the CRH stimulation test and peak cortisol levels during the GHRP-2 test would effectively support hypothalamic SAI diagnosis.